A survey of 539 people with Lynch syndrome highlights a gap between evidence supporting aspirin-based cancer prevention and its implementation in clinical practice, despite strong interest in preventive research.
A new study led by researchers at University Hospital Bonn (UKB), the University of Bonn and the Center for Integrated Oncology (CIO) Bonn has highlighted the limited use of aspirin for colorectal cancer prevention among people with Lynch syndrome. Published as a letter in The Lancet Gastroenterology & Hepatology, the findings show that although most respondents were aware of screening recommendations, only a small proportion reported taking aspirin specifically to reduce their cancer risk.
Lynch syndrome is an inherited condition associated with an increased risk of colorectal cancer and several other cancers. Aspirin, also known as acetylsalicylic acid, has been investigated as a preventive option for people with this hereditary predisposition.
The CAPP2 study previously demonstrated a long-term reduction in colorectal cancer risk among people with Lynch syndrome who received 600 mg of aspirin daily. More recently, the international CaPP3 study suggested that a lower daily dose of 100 mg could offer a similar cancer-preventive profile, potentially with better tolerability and fewer bleeding complications.
However, the researchers caution that formal statistical equivalence was not established in every analysis. Therefore, the findings should be interpreted carefully, and the appropriate aspirin dose must be determined through an individualized medical assessment.
The LYNX study surveyed 539 people with Lynch syndrome across Germany between December 2025 and February 2026. The survey was designed before the publication of the CaPP3 findings and therefore reflects aspirin use based on the evidence available at that time.
The results revealed a substantial difference between awareness of preventive care and the use of medication for cancer prevention. Approximately 97% of respondents were familiar with specific screening recommendations, and nearly all reported undergoing regular colonoscopies. Despite this high level of awareness, only 10.4% said they were currently taking aspirin.
More importantly, just 6.9% of all respondents reported using aspirin specifically for cancer prevention associated with Lynch syndrome.
According to the researchers, the most frequently cited reasons for not using aspirin included limited prior engagement with the subject, concerns about potential side effects and uncertainty regarding the available scientific evidence.
The survey also explored attitudes toward emerging preventive approaches, including mRNA-based cancer vaccines. Approximately three-quarters of participants said they could imagine taking part in a clinical study investigating a preventive mRNA cancer vaccine. After receiving additional information, the proportion increased to around 80%.
Furthermore, more than 92% of respondents said they would want to receive such a vaccine if it were approved in the future. A majority of participants were also willing to accept the possibility of being assigned to a placebo group and acknowledged the potential risk of side effects associated with preventive research. These findings indicate considerable interest among people with Lynch syndrome in exploring new approaches that could help reduce their inherited cancer risk.
The LYNX study suggests that the limited use of aspirin is not necessarily due to a lack of interest in cancer prevention. Instead, the findings point to an implementation gap between scientific evidence, medical counselling and actual clinical practice.
The researchers emphasize the importance of providing early, accessible and structured information about aspirin chemoprevention. Discussions should address the potential benefits, limitations and risks of treatment, allowing healthcare professionals and patients to make decisions based on individual circumstances.
Collaboration with the German Consortium Familial Colorectal Cancer and the self-help organization SemiColon played an important role in reaching participants and incorporating patient perspectives into the research. The study also demonstrates the value of involving people affected by hereditary cancer syndromes in the development and evaluation of preventive strategies.
The findings highlight an important challenge in hereditary cancer care: scientific evidence alone may not be sufficient to ensure that preventive options are understood and appropriately considered in clinical practice.
For people with Lynch syndrome, regular colonoscopic surveillance remains an important component of cancer prevention and early detection. Aspirin may offer an additional preventive option for selected individuals, but its use requires consideration of bleeding risks, other medical conditions, concurrent medications and the available evidence.
The publication of the CaPP3 findings may encourage further discussion about lower-dose aspirin regimens. Future research will be needed to determine whether this evidence leads to greater uptake of aspirin chemoprevention and whether educational interventions can help close the gap between research and routine care.
